Transgene is designing and developing next-generation immunotherapeutics against cancer
TG4050
First positive data
from Phase I clinical trials
–> article annonceHome
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
Discover invir.IO™
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously 
ESMO 2021
Donwload Press release (PDF)
TG6002 en images 
Transgene in a nutshell
–> article Home actus
Press releases
- November 22, 2021 - Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
- November 17, 2021 - Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
- November 17, 2021 - Transgene reports business update and Q3 2021 financial position
- November 9, 2021 - Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
Last publications
- September 23, 2021 - Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- November 9, 2020 - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
- November 9, 2020 - TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
- June 22, 2020 - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
Latest webcasts
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- March 11, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001 (in French)
- March 10, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001
